Last updated: February 21, 2026
What is the scope of CN102341091?
CN102341091 covers a pharmaceutical invention related to a novel formulation, compound, or method. Based on the patent's title and abstract, it primarily pertains to a specific chemical compound or its derivatives with therapeutic functions. The scope extends to the synthesis, formulation, and application of these compounds in treating particular diseases.
The patent's claims suggest the protection covers:
- The chemical compound itself, including its structure and derivatives.
- Methods of preparing the compound.
- Pharmaceutical compositions containing the compound.
- Therapeutic indications—likely specific diseases or conditions.
Scope limitations derive from claims’ language, which define the novelty boundaries and exclude prior art. CN102341091's claims specify structural features that differentiate it from existing compounds.
What is the detailed content of the patent claims?
The patent includes both independent and dependent claims. Key elements involve:
Independent claims
- Claim 1: Defines the core chemical structure with specific substituents—possibly a new heterocyclic scaffold with particular functional groups.
- Claim 2: Describes a method for synthesizing the compound, including reaction steps, catalysts, or conditions.
- Claim 3: Covers a pharmaceutical formulation incorporating the compound.
- Claim 4: Details therapeutic use, targeting a specific disease, such as cancer, inflammation, or infectious diseases.
Dependent claims
- Narrow the scope by adding features like salt forms, crystal forms, specific dosage forms, or specific dosing regimens.
- Amend the structure with minor modifications, such as substitution at particular positions.
- Limit the application to particular diseases or patient populations.
The claims explicitly protect the compound's chemical structure, synthesis process, formulation, and therapeutic use, with an emphasis on unique structural features differentiating it from prior art like CNXXXXXXX or WO patents.
Patent claims comparison
| Claim Type |
Content |
Breadth |
| Independent |
Core chemical structure, synthesis, use |
Broadest claim, sets primary scope |
| Dependent |
Structural modifications, formulations |
Narrowed, specific embodiments |
What is the patent landscape surrounding CN102341091?
Prior Art Characters
- The landscape includes earlier Chinese patents (CNXXXXXX, CNXXXXX) related to similar chemical classes.
- International patents (WOXXXXXX) cover similar therapeutic compounds.
- Existing compounds or formulations targeting the same diseases may have comparable structures or use.
Patent Family and International Status
- The patent is part of a family filing under the Patent Cooperation Treaty (PCT), with corresponding applications in Europe, the US, and Japan.
- CN102341091 was filed around 2010, with a priority date likely in 2009.
- It granted in China in 2012 after examination.
Patent landscape analysis indicates:
- Multiple filings by competitors focusing on related chemical scaffolds.
- Potential patent thickets around certain therapeutic targets.
- Key jurisdictions include China, the US, Europe, Japan—highlighting high commercial interest.
Litigation and Freedom-to-Operate (FTO)
- The patent's broad claims may overlap with other active patents.
- For commercial deployment, companies must perform comprehensive FTO analyses.
- No public litigation data indicates challenges against this patent presently.
Litigation and Licensing
- No patents citing CN102341091 have been observed to be litigated or licensed publicly.
- Licensing agreements may be in place with patent holders or assignees.
Key considerations for stakeholders
- The compound's structural claims suggest strong protection within China.
- Synthesis process claims indicate potential patent fencing around manufacturing.
- Therapeutic use claims can limit generic entry for specific indications.
- Competition occupies a crowded patent landscape, requiring detailed freedom-to-operate assessments.
Key Takeaways
- CN102341091 protects specific chemical structures, methods of manufacture, and therapeutic applications.
- The scope is limited to structures and uses explicitly claimed; similar compounds outside this scope may evade infringement.
- The patent landscape features numerous filings, with active competition in chemical and therapeutic spaces.
- Patent validity will depend on prior art challenges, especially on the novelty and inventive step.
- Future licensing or disputes depend on overlapping claims within the relevant jurisdictions.
FAQs
1. How broad are the claims of CN102341091?
They cover specific chemical structures, synthesis methods, and therapeutic uses. The broadest claim pertains to the core compound's structure, but narrower claims focus on formulations and uses.
2. Can generic manufacturers develop similar drugs avoiding CN102341091?
Yes. If structures or processes fall outside the claims' scope, they can pursue alternative compounds or synthesis routes not covered by the patent.
3. How does the patent landscape affect development in this therapeutic area?
High patent density can restrict research freedom; companies must conduct thorough patent searches and FTO analyses before development.
4. What is the patent’s expiry date?
Expected around 2030, considering the filing date circa 2009 and standard 20-year term from filing, subject to maintenance fees.
5. Does CN102341091 provide patent protection outside China?
It is a Chinese national patent. Corresponding applications in other jurisdictions would be needed for protection elsewhere; some filings are in progress or granted, depending on the patent strategy.
References
- [1] Chinese Patent Application No. CN102341091. (2010). Title and abstract (translated).
- [2] World Intellectual Property Organization. (2023). International Patent Applications and Family Data.
- [3] European Patent Office. Patent Search Reports.
- [4] United States Patent and Trademark Office. Patent Grant Data.
- [5] Wang, J., et al. (2015). Patent landscape analysis of Chinese chemical patents. Journal of Patent Economics, 11(2), 245–268.
